全文获取类型
收费全文 | 10838篇 |
免费 | 723篇 |
国内免费 | 112篇 |
专业分类
耳鼻咽喉 | 98篇 |
儿科学 | 259篇 |
妇产科学 | 85篇 |
基础医学 | 1236篇 |
口腔科学 | 282篇 |
临床医学 | 813篇 |
内科学 | 2984篇 |
皮肤病学 | 406篇 |
神经病学 | 608篇 |
特种医学 | 489篇 |
外国民族医学 | 1篇 |
外科学 | 1889篇 |
综合类 | 122篇 |
一般理论 | 3篇 |
预防医学 | 291篇 |
眼科学 | 123篇 |
药学 | 704篇 |
2篇 | |
中国医学 | 39篇 |
肿瘤学 | 1239篇 |
出版年
2023年 | 161篇 |
2022年 | 334篇 |
2021年 | 513篇 |
2020年 | 266篇 |
2019年 | 333篇 |
2018年 | 415篇 |
2017年 | 387篇 |
2016年 | 410篇 |
2015年 | 393篇 |
2014年 | 507篇 |
2013年 | 524篇 |
2012年 | 840篇 |
2011年 | 876篇 |
2010年 | 455篇 |
2009年 | 374篇 |
2008年 | 633篇 |
2007年 | 682篇 |
2006年 | 597篇 |
2005年 | 562篇 |
2004年 | 461篇 |
2003年 | 359篇 |
2002年 | 298篇 |
2001年 | 96篇 |
2000年 | 71篇 |
1999年 | 69篇 |
1998年 | 50篇 |
1997年 | 45篇 |
1996年 | 31篇 |
1995年 | 21篇 |
1994年 | 26篇 |
1993年 | 20篇 |
1992年 | 69篇 |
1991年 | 62篇 |
1990年 | 48篇 |
1989年 | 50篇 |
1988年 | 63篇 |
1987年 | 58篇 |
1986年 | 52篇 |
1985年 | 48篇 |
1984年 | 37篇 |
1983年 | 21篇 |
1982年 | 22篇 |
1979年 | 24篇 |
1978年 | 26篇 |
1977年 | 36篇 |
1976年 | 24篇 |
1973年 | 25篇 |
1972年 | 20篇 |
1970年 | 24篇 |
1967年 | 20篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
991.
Terauchi T Tateishi U Maeda T Kanou D Daisaki H Moriya Y Moriyama N Kakizoe T 《Japanese journal of clinical oncology》2007,37(10):797-800
[C-11] choline positron emission tomography ([C-11] choline PET) has been expected to be one of the new PET modalities similar to [F-18] fuluorodeoxyglucose positron emission tomography (FDG-PET), which has spread worldwide as a gold standard of PET oncologic imaging. However, there has been no report on [C-11] choline PET used for detection of colorectal cancer, which is one of major targets of oncologic FDG-PET. We initiated the research to investigate the detectability of [C-11] choline PET for various tumors including colorectal cancer. This is the first report of a patient who underwent surgical resection for advanced colon cancer depicted by [C-11] choline positron emission tomography/computed tomography. 相似文献
992.
Ichimatsu D Nomura M Nakamura S Moritani S Yokogawa K Kobayashi S Nishioka T Miyamoto K 《Molecular carcinogenesis》2007,46(6):436-445
We found that quercetin, myricetin, quercetagetin, fisetin, (-)-epigallocatechin gallate (EGCG), and theaflavins, among 24 flavonoids examined, markedly inhibited epidermal growth factor (EGF)-induced cell transformation of mouse epidermal JB6 Cl 41 cells. The six flavonoids suppressed the EGF-induced activation of activator protein 1 (AP-1). In addition, myricetin, quercetagetin, EGCG, and theaflavins directly inhibited EGF-induced phosphatidylinositol 3-kinase (PI3K) activation. The important structural features of flavonoids for cell transformation-inhibitory activity are 3'- and 4'-OH on the B-ring, 3-OH on the C-ring, C2=C3 double bond in the C-ring, and the phenylchromone (C6-C5-C6) skeleton in the flavonols, and the galloyl group in EGCG and theaflavins. Our results provide new insight into possible mechanisms of the anti-carcinogenic effects of flavonoids, and could help to provide a basis for the design of novel cancer chemopreventive agents. 相似文献
993.
This study was designed to elucidate the therapeutic effect of transfering the brain-specific angiogenesis inhibitor 1 (BAI1) gene to a mouse renal cell carcinoma cell line (Renca). Female BALB/c mice were inoculated subcutaneously with wild-type Renca (Renca/Wild) cells or Renca cells transfected with the BAI-1 (Renca/BAI-1) or LacZ (Renca/LacZ) gene. Tumor growth was observed every other day from 3 to 35 days after implantation. Moreover, the intratumoral injection of the adenovirus vector containing the gene encoding BAI1 was conducted at two-day intervals from 11 to 31 days after implantation of the Renca/Wild or Renca/BAI1 tumor. Tumor blood flow was measured by colorimetric angiogenesis assay (CAA). The concentration of the vascular endothelial growth factor (VEGF) in the cell culture supernatants was determined by enzyme-linked immunoassay. The size of the Renca/BAI1 tumor was significantly (p<0.01) suppressed compared to the Renca/Wild and Renca/LacZ tumors 21 days after tumor implantation. The injection of the BAI1 viral vector at 2-day intervals significantly inhibited the growth of both the Renca/Wild and Renca/BAI1 tumors. The blood volume measured by CAA and microvessel density was significantly lower in the Renca/BAI1 than in the Renca/Wild and Renca/LacZ tumors (p<0.01 and p<0.05, respectively). A significant (p<0.01) reduction in VEGF concentration in the supernatant was demonstrated in the Renca/BAI1 compared with the Renca/Wild and Renca/LacZ cell cultures. These observations suggest that the transfer of the BAI1 gene to Renca can suppress the tumor growth via the inhibition of angiogenesis. The down-regulation of VEGF production in tumor cells contributes to this anti-tumor effect. 相似文献
994.
Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma 总被引:2,自引:0,他引:2
Fujita K Sano D Kimura M Yamashita Y Kawakami M Ishiguro Y Nishimura G Matsuda H Tsukuda M 《Oncology reports》2007,18(1):47-51
Human tumors are dependent on angiogenesis for growth, and the vascular endothelial growth factor (VEGF) is a major regulator of this process. Bevacizumab (Avastin), a monoclonal antibody directed against VEGF, has shown promise in treating a variety of cancers. In this study, we first examined the anti-tumor effects of bevacizumab on head and neck squamous cell carcinoma (HNSCC). Then we examined the effects of bevacizumab combined with paclitaxel, a chemotherapeutic agent, in HNSCC. This is the first demonstration of the anti-tumor effects of bevacizumab on HNSCC. In vitro, bevacizumab did not show any antiproliferative effects against the HNSCC cell lines. However, in vivo, bevacizumab showed dramatic anti-tumor effects against HNSCC tumor xenografts in mice. In addition, treatment with a bevacizumab-paclitaxel combination resulted in a remarkable inhibition of the HNSCC tumor xenografts, compared to the effects of each agent separately. A decreased blood vessel density and an increased apoptotic index were seen in the shrunken tumors. These results suggest that bevacizumab in combination with paclitaxel could have useful clinical application in HNSCC. 相似文献
995.
996.
Population pharmacokinetics of darbepoetin alfa in haemodialysis and peritoneal dialysis patients after intravenous administration 下载免费PDF全文
Takama H Tanaka H Nakashima D Ogata H Uchida E Akizawa T Koshikawa S 《British journal of clinical pharmacology》2007,63(3):300-309
AIMS: To characterize the pharmacokinetics of darbepoetin alfa and covariate relationships in haemodialysis (HD) and peritoneal dialysis (PD) patients. METHODS: Data were collected from 131 (63 HD and 68 PD) patients who received darbepoetin alfa intravenously. A total of 917 serum concentrations were available. The data were analysed by nonlinear mixed effect modelling using NONMEM with a model including endogenous erythropoietin production. In addition, the final model was evaluated using bootstrap resampling. RESULTS: The selected basic model was a two-compartment model with a combination of additive and the constant coefficient of variation error models. The significant covariates were weight (WT) for clearance (CL) and the volume of central compartment (V(1)), and the dialysis technique (DIA) for V(1). The typical values of CL and V(1) were 0.0807 l h(-1) and 2.51 l, respectively. V(1) in PD patients was 17% higher than in HD patients. With the introduction of WT in CL and WT and DIA in V(1), interindividual variability decreased from 27.1% to 20.6% in CL and from 29.1% to 21.8% in V(1). The mean parameter estimates from the bootstrap datasets were similar to those from the original dataset. Evaluation by bootstrapping showed that the final model was stable. CONCLUSIONS: The results of the present analysis suggest no dosage regimen change is warranted for darbepoetin alfa in HD and PD patients over the range of distribution of covariates included in this study. 相似文献
997.
998.
Yutaka Kurebayashi Hanako Tsujikawa Katsutoshi Sugimoto Daisuke Yunaiyama Yoichi Araki Kazuhiro Saito Hiroshi Takahashi Tatsuya Kakegawa Takuya Wada Yusuke Tomita Masakazu Abe Yu Yoshimasu Hirohito Takeuchi Taiki Hirata Kentaro Sakamaki Kazuhiro Kakimi Toshitaka Nagao Takao Itoi Michiie Sakamoto 《Hepatology research》2023,53(10):1008-1020
999.
1000.
Daisuke Minakata Shin-ichiro Fujiwara Daizo Yokoyama Atsuto Noguchi Shuka Aoe Takashi Oyama Shunsuke Koyama Rui Murahashi Hirotomo Nakashima Kazuki Hyodo Takashi Ikeda Shin-ichiro Kawaguchi Yumiko Toda Shoko Ito Takashi Nagayama Kiyomi Mashima Kento Umino Kaoru Morita Masahiro Ashizawa Chihiro Yamamoto Kaoru Hatano Kazuya Sato Ken Ohmine Yoshinobu Kanda 《British journal of haematology》2023,200(6):694-703
The prognosis of multiple myeloma (MM) has dramatically improved with the development of new drugs, and it has become important to determine the appropriate combinations of these novel agents. This study was a systematic review and network meta-analysis (NMA) of randomized trials in patients with relapsed and/or refractory (RR) MM. The PubMed, Cochrane, and Embase databases were searched for randomized trials from 1 January 2002 to 28 February 2022 of patients treated for MM. The primary end-point was progression-free survival (PFS), evaluated as a hazard ratio (HR) with a 95% confidence interval (95% CI) compared to dexamethasone (DEX). The p-score was used to rank treatments. Of a total of 1136 abstracts screened, 37 studies were selected, including 34 treatment options for RRMM. Daratumumab, lenalidomide and DEX was found to be the best treatment for RRMM, with the best HR compared to DEX (HR, 0.13; 95% CI, 0.08–0.20; p-score 0.9796). There was no evidence of significant heterogeneity (I2, 41.3%; p = 0.146). The current NMA confirmed the excellent efficacy of three-drug regimens including anti-CD38 antibodies to treat RRMM and provides background data to evaluate the efficacy of chimeric antigen receptor T-cell treatments and bispecific T-cell engager therapies. 相似文献